Naïla Aba

Naïla Aba

Auto-generated profile, based on publicly available information

Naïla Aba

Centre for Research in Epidemiology and Population Health (CESP), INSERM Unit 1018, Radiation Epidemiology team , 39 rue Camille Desmoulins Villejuif 94800

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
PDF file
NANaïla Aba
Naïla Aba
CDClaire Ducos
Claire Ducos
EMEric Morel
Eric Morel
CFChiraz El Fayech
Chiraz El Fayech
BFBrice Fresneau
Brice Fresneau
NHNadia Haddy
Nadia Haddy
Childhood cancer survivors (CCS) often suffer from cardiac disease (CD) after treatment that included anthracycline and radiotherapy involving the heart. However, the variability in CD occurrence cannot be explained solely by these treatments, suggesting the existence of genetic predisposition. We conducted a systematic review searching on Medline-PubMed and Scopus, to identify studies reporting associations between genetic factors and CD in CCS. We included studies published up to 11 April 2023, with no lower limit, and assessed the quality of genetic associations by the Q-genie tool. As a result, 20 studies were included (15 case-control and five cohorts), revealing several genes and variants associated with cardiomyopathy, among which, SLC28A3-rs7853758, RARG-rs2229774, P2RX7-rs208294 and P2RX7-rs3751143 variants gave the most consistent findings. This review highlights the necessity to establish a set of clinically useful genes and variants to identify patients most at risk of developing cardiomyopathy, and to implement monitoring and prevention strategies.

23 September 2025 in European Heart Journal
Verified
Journal Article
Open access
NANaïla Aba
Naïla Aba
GTGwénaël Le Teuff
Gwénaël Le Teuff
BFBrice Fresneau
Brice Fresneau
SKSerge Koscielny
Serge Koscielny
SBShaima Belhechmi
Shaima Belhechmi
NHNadia Haddy
Nadia Haddy
Background and Aims: Cardiotoxic treatments like anthracyclines and heart-directed radiotherapy increase the risk of cardiac diseases (CDs) in childhood cancer survivors (CCSs), but individual differences in CD incidence are not fully understood. This study aims to identify transcriptomic biomarkers associated with CD occurrence after childhood cancer treatment. Methods: A matched case-control study was conducted on a sample of 330 CCS: 165 cases with CD and 165 CD-free controls. The expression of 8557 genes was investigated to select those associated with CD and heart failure (HF), using three stabilization approaches derived for the conditional logistic regression with Lasso (Percentile lasso, Bolasso, and Sublasso). The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated. Results: One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09–.29; HF: OR .11, 95% CI .03–.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study. Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77]. Conclusions: Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS. Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

27 May 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
CDClaire Ducos
Claire Ducos
NANaïla Aba
Naïla Aba
FRFilippo Rosselli
Filippo Rosselli
BFBrice Fresneau
Brice Fresneau
BNBaraah Al Ahmad Nachar
Baraah Al Ahmad Nachar
NHNadia Haddy
Nadia Haddy
Second malignant neoplasm (SMN) is one of the most severe long-term risks for childhood cancer survivors (CCS), significantly impacting long-term patient survival. While radiotherapy and chemotherapy are known risk factors, the observed inter-individual variability suggests a genetic component contributing to the risk of SMN. This article aims to conduct a systematic review of genetic factors implicated in the SMN risk among CCS. Searches were performed in PubMed, Scopus, and Web of Sciences. Eighteen studies were included (eleven candidate gene studies, three genome-wide association studies, and four whole exome/genome sequencing studies). The included studies were based on different types of first cancers, investigated any or specific types of SMN, and focused mainly on genes involved in drug metabolism and DNA repair pathways. These differences in study design and methods used to characterize genetic variants limit the scope of the results and highlight the need for further extensive and standardized investigations. However, this review provides a valuable compilation of SMN risk-associated variants and genes, facilitating efficient replication and advancing our understanding of the genetic basis for this major risk for CCS.

17 June 2026
Verified
Other
Open access
CDClaire Ducos
Claire Ducos
NANaïla Aba
Naïla Aba
FRFilippo Rosselli
Filippo Rosselli
BFBrice Fresneau
Brice Fresneau
BNBaraah Al Ahmad Nachar
Baraah Al Ahmad Nachar
NHNadia Haddy
Nadia Haddy
Table S2 displays all the keywords used to search articles in the Scopus database.

17 June 2026
Verified
Other
Open access
PDF file
CDClaire Ducos
Claire Ducos
NANaïla Aba
Naïla Aba
FRFilippo Rosselli
Filippo Rosselli
BFBrice Fresneau
Brice Fresneau
BNBaraah Al Ahmad Nachar
Baraah Al Ahmad Nachar
NHNadia Haddy
Nadia Haddy
Table S4 presents the quality control results using the q-genie scale for each article included in this review.

1 August 2024
Verified
Other
Open access
CDClaire Ducos
Claire Ducos
NANaïla Aba
Naïla Aba
FRFilippo Rosselli
Filippo Rosselli
BFBrice Fresneau
Brice Fresneau
BNBaraah Al Ahmad Nachar
Baraah Al Ahmad Nachar
NHNadia Haddy
Nadia Haddy
Second malignant neoplasm (SMN) is one of the most severe long-term risks for childhood cancer survivors (CCS), significantly impacting long-term patient survival. While radiotherapy and chemotherapy are known risk factors, the observed inter-individual variability suggests a genetic component contributing to the risk of SMN. This article aims to conduct a systematic review of genetic factors implicated in the SMN risk among CCS. Searches were performed in PubMed, Scopus, and Web of Sciences. Eighteen studies were included (eleven candidate gene studies, three genome-wide association studies, and four whole exome/genome sequencing studies). The included studies were based on different types of first cancers, investigated any or specific types of SMN, and focused mainly on genes involved in drug metabolism and DNA repair pathways. These differences in study design and methods used to characterize genetic variants limit the scope of the results and highlight the need for further extensive and standardized investigations. However, this review provides a valuable compilation of SMN risk-associated variants and genes, facilitating efficient replication and advancing our understanding of the genetic basis for this major risk for CCS.